Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.
Menu

Celcuity Inc (CELC)

Celcuity Inc (CELC)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Celcuity Faces Widening Losses as Analysts Await Critical Earnings Report Barchart - Tue Mar 24, 4:04PM CDT

CELC : 102.01 (-4.44%)
Celcuity Schedules Release of Fourth Quarter and Full Year 2025 Financial Results and Webcast/Conference Call GlobeNewswire - Wed Mar 18, 7:00AM CDT

MINNEAPOLIS, March 18, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that it will...

CELC : 102.01 (-4.44%)
Celcuity Announces Publication of Results from PIK3CA Wild-Type Cohort of Phase 3 VIKTORIA-1 Study of Gedatolisib Regimens in HR+/HER2- Advanced Breast Cancer in Journal of Clinical Oncology GlobeNewswire - Mon Mar 9, 4:42PM CDT

As previously presented, gedatolisib + palbociclib + fulvestrant (“gedatolisib triplet”) and gedatolisib + fulvestrant (“gedatolisib doublet”) reduced the risk of disease progression or death versus...

CELC : 102.01 (-4.44%)
Celcuity To Participate in Upcoming Investor Conferences GlobeNewswire - Wed Feb 25, 3:01PM CST

MINNEAPOLIS, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that Brian...

CELC : 102.01 (-4.44%)
Celcuity Appoints Charles Romp to its Board of Directors GlobeNewswire - Thu Feb 12, 3:05PM CST

MINNEAPOLIS, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced the appointment...

CELC : 102.01 (-4.44%)
Celcuity to Present at Upcoming Guggenheim Emerging Outlook: Biotech Summit 2026 GlobeNewswire - Wed Feb 4, 6:05AM CST

MINNEAPOLIS, Feb. 04, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced its participation...

CELC : 102.01 (-4.44%)
Celcuity Announces FDA Acceptance of New Drug Application for Gedatolisib in HR+/HER2-/PIK3CA Wild-Type Advanced Breast Cancer GlobeNewswire - Tue Jan 20, 6:30AM CST

FDA grants Priority Review and assigns a PDUFA goal date of July 17, 2026 MINNEAPOLIS, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing...

CELC : 102.01 (-4.44%)
Novel Modalities Drive $668B Precision Oncology Expansion BayStreet.ca - Fri Jan 2, 10:34AM CST

Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – Baystreet.ca News Commentary – The global oncology market is projected to reach US$668.26 billion by 2034[1], as investors increasingly...

ONCY : 0.9235 (-2.51%)
PSTV : 0.2399 (-1.80%)
IMNM : 20.21 (-2.60%)
BCYC : 4.50 (+3.69%)
CELC : 102.01 (-4.44%)
Celcuity Presents Updated Results from the PIK3CA Wild-Type Cohort of the Phase 3 VIKTORIA-1 Trial at the 2025 San Antonio Breast Cancer Symposium GlobeNewswire - Thu Dec 11, 2025

For patients whose time to progression on immediate prior therapy was >18 months, median progression-free survival (“PFS”) was 12.4 months with gedatolisib + palbociclib + fulvestrant (“gedatolisib...

CELC : 102.01 (-4.44%)
MarketBeat.com
3 Stocks You’ll Wish You Bought Before 2026 MarketBeat - Wed Dec 3, 2025

These three up-and-coming stocks are delivering massive 2025 gains and may have more room to run as key catalysts unfold

DAVE : 206.40 (-4.16%)
CELC : 102.01 (-4.44%)
TDUP : 3.46 (-0.29%)

Barchart Exclusives

The Top High-Yield Dividend Stock to Buy Now for Oil Price Protection Barchart - Tue Mar 24, 6:30PM CDT
As the situation remains tense, this high dividend-paying consumer staple company can be a prudent choice for investors. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.